News coverage about Incyte (NASDAQ:INCY) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Incyte earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.9732304000129 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
INCY has been the topic of a number of research reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte in a report on Wednesday, October 25th. BidaskClub cut shares of Incyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Royal Bank of Canada raised shares of Incyte from a “sector perform” rating to an “outperform” rating and set a $136.00 price target on the stock in a report on Tuesday, January 2nd. Cowen reaffirmed a “buy” rating on shares of Incyte in a report on Tuesday, December 5th. Finally, Deutsche Bank started coverage on shares of Incyte in a report on Tuesday, December 12th. They set a “hold” rating and a $106.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Incyte presently has a consensus rating of “Buy” and an average target price of $143.25.
Incyte (NASDAQ:INCY) traded up $3.02 on Monday, hitting $87.52. 1,750,000 shares of the stock were exchanged, compared to its average volume of 1,800,000. The stock has a market cap of $18,470.00, a price-to-earnings ratio of -109.40 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. Incyte has a 12-month low of $80.85 and a 12-month high of $153.15.
In other news, EVP Vijay K. Iyengar sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total transaction of $486,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David W. Gryska sold 6,760 shares of the business’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the transaction, the insider now owns 20,752 shares of the company’s stock, valued at $2,051,750.24. The disclosure for this sale can be found here. Insiders have sold a total of 40,963 shares of company stock valued at $4,222,953 over the last 90 days. Company insiders own 17.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Incyte (INCY) Stock Price” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-incyte-incy-stock-price.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.